Instructions for Anginovag oral spray bottle 20 ml
Composition
active ingredients: dequalinium chloride, tyrothricin, enoxolone (β-glycyrrhetinic acid), hydrocortisone acetate, lidocaine hydrochloride;
1 ml of spray contains: dequalinium chloride 1 mg; tyrothricin 4 mg; enoxolone (β-glycyrrhetinic acid) 0.6 mg; hydrocortisone acetate 0.6 mg; lidocaine hydrochloride 1 mg;
excipients: propylene glycol, pineapple oil, sodium saccharin, ethanol 96% (v/v).
Dosage form
Oral spray.
Main physicochemical properties: clear solution from colorless to slightly yellowish.
Pharmacotherapeutic group
Medicines used for throat diseases. Antiseptics. ATX code R02A A20.
Pharmacological properties
Pharmacodynamics
Anginovag combines substances with anti-inflammatory, analgesic, antibacterial, and antiseptic effects, which exhibit a complementary and synergistic effect.
These pharmacological properties provide comprehensive pathogenetic therapy for inflammatory diseases of the upper respiratory tract and oral mucosa.
Tyrothricin is a topical antibiotic produced by the bacterium Bacillus Brevis Dubos. It is active against many gram-positive bacteria.
Dequalinium chloride is an antiseptic and disinfectant. It has demonstrated activity against many bacteria, yeasts, and fungi.
Hydrocortisone acetate is an anti-inflammatory agent specific for primary and secondary inflammation in the acute stage of the inflammatory process.
Enoxolone is a potent inhibitor of the enzyme 11-hydroxysteroid dehydrogenase. Enoxolone has been shown to potentiate cortisol activity when used concomitantly.
Lidocaine hydrochloride is a local anesthetic of the amide group. It acts by inhibiting ionic reflexes necessary for the stimulation and conduction of nerve impulses.
Pharmacokinetics
No systemic absorption of any of the active ingredients was detected.
Indication
Local treatment of infectious and inflammatory diseases of the oral cavity and upper respiratory tract: tonsillitis, pharyngitis, laryngitis, aphthous and ulcerative stomatitis, glossitis.
Contraindication
Increased individual sensitivity (allergy) to any component of the drug.
Interaction with other medicinal products and other types of interactions
The drug contains ethanol, which may change or enhance the effects of other medications.
The antibacterial activity of dequalinium is reduced when used simultaneously with anionic surfactants, for example, when using toothpaste.
Application features
The drug contains ethanol. Each application contains approximately 0.075 g of ethanol, which may be harmful to patients with alcoholism. Caution should be exercised when used in pregnant and breastfeeding women, children, and patients with liver disease and epilepsy.
While taking Anginovag, a positive doping test is possible.
The drug may cause skin irritation because it contains propylene glycol.
Avoid getting the spray in your eyes.
Visual impairment
Visual disturbances may occur with systemic or topical corticosteroids. If a patient experiences symptoms such as blurred vision or other visual disturbances, they should consult an ophthalmologist to determine possible causes, which may include cataracts, glaucoma, or rare conditions such as central serous chorioretinopathy (CSR), which has been reported following the use of systemic or topical corticosteroids.
Use during pregnancy or breastfeeding
There are no clinical data on the use of Anginovag during pregnancy or breastfeeding.
Ability to influence reaction speed when driving vehicles or other mechanisms
There is no data on the harmful effects on the ability to drive a car and operate other mechanisms.
Method of administration and doses
Use in adults and children over 13 years of age. Before use, if necessary, rinse the mouth and throat with boiled warm water. Remove necrotic plaque from the affected areas (ulcers, erosions) with a swab. The first two days - 1 - 2 injections every 2 - 3 hours, then - 1 injection every 6 hours. The course of treatment is determined by the doctor individually, usually it is 5 - 7 days.
Method of application.
For proper use, it is recommended to hold the bottle vertically; direct the oral applicator towards the affected area, but do not insert it completely into the mouth. Press the top of the cap from top to bottom.
The bottle is equipped with a dosing valve: each full press causes a controlled release of medication.
Children
Due to the lack of clinical data for this age group, Anginovag is not recommended for use in children under 13 years of age.
Overdose
No cases of overdose have been described.
Side effects
When using Anginovag, in some cases, depending on the patient's hypersensitivity to the components of the drug, local irritation is possible, which is usually temporary.
Below are the side effects that may occur in the case of monotherapy with one of the active ingredients of the drug Anginovag:
Dequalinium chloride
Sometimes hypersensitivity reactions may occur after using the drug, such as rash, itching, burning sensation, irritation of the mucous membrane of the mouth and throat. In rare cases, namely in case of abuse, ulceration and necrosis may occur. In case of any unusual reactions, the drug should be discontinued and a doctor should be consulted regarding further therapy.
Tyrothricin
Hypersensitivity.
Contraindicated for intranasal use; there are reports that this route of administration may cause impaired sense of smell.
Hydrocortisone acetate
Hydrocortisone is a steroid component of the drug that can cause local adverse reactions, such as burning, itching, irritation at the site of application, excessive drying, atrophic skin changes, contact dermatitis, eczema, rosacea-like dermatitis, inflammation of the skin around the lips, skin maceration, acne-like rashes, dermectasias, sweating, rashes, hypertrichosis, skin depigmentation, secondary skin infections and folliculitis, rebound effect, which can lead to steroid dependence; purpura, striae; delayed wound healing. Increased intraocular pressure and risk of cataracts (with systematic contact of the drug with the conjunctiva).
With prolonged use of the drug and/or application to extensive areas of the skin, hydrocortisone may penetrate the bloodstream and cause systemic undesirable symptoms typical of corticosteroids, including suppression of adrenal function.
Visual disturbances: Frequency unknown: blurred vision (for detailed information see section "Special instructions for use.")
Lidocaine hydrochloride
Local effects. When using the drug, a burning sensation may occur, which disappears after the anesthetic effect appears (within 1 minute).
Transient erythema, edema, and decreased sensitivity may occur at the site of application.
Allergic reactions, including skin rash, itching, urticaria, angioedema, bronchospasm, and in extremely severe cases, shock.
If hypersensitivity reactions occur, the use of the drug should be discontinued.
Systemic effects. If the drug is used according to the instructions, the incidence of systemic effects is extremely low, since the amount of active substance that can reach the bloodstream is very small. When using high doses and in the case of rapid absorption of lidocaine or in case of hypersensitivity, idiosyncrasy or reduced tolerance, the following side effects may develop:
from the side of the central nervous system: excitement, depression, nervousness, dizziness, drowsiness, spasms, loss of consciousness, respiratory paralysis;
Cardiovascular system: hypotension, myocardial infarction, bradycardia.
Expiration date
4 years.
Storage conditions
Store at a temperature not exceeding 30 °C.
Incompatibility
Not described.
Packaging
10 ml or 20 ml in a bottle; 1 bottle together with an oral dispenser in a cardboard box.
Vacation category
Without a prescription.
Producer
Ferrer International, S.A.
Location of the manufacturer and its business address
Legal address
Gran Via Carlos III, 94, 08028, Barcelona, Spain.
Place of production
s/Joan Buscaya, 1-9, 08173 Sant Cugat del Bayes (Barcelona), Spain.
